BPC-157: what the research shows, the risks and its FDA status

BPC-157 is a synthetic peptide (a short chain of 15 amino acids) modelled on a protein in human stomach juice. In rats it speeds the healing of cut tendons, damaged gut lining and torn muscle ¹. In people it has been tried in four small published reports of 2 to 16 patients, none with a comparison group. It has never been approved as a medicine anywhere, and WADA (the World Anti-Doping Agency) bans it in sport at all times ¹⁶. This page sets out what is known so you can weigh the claims and talk them through with a clinician.

What is BPC-157?

BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid fragment of a larger protein first found in human gastric juice, and the version sold today is made in a lab. Its developers describe it as cytoprotective, meaning it appears to protect and repair tissue in animal models, rather than acting on one known receptor the way most drugs do.

You will see it sold as a plain form, an acetate salt or an arginate salt. These are the same peptide packaged slightly differently for shelf stability, and no study in people has compared them.

Where BPC-157 came from

Almost all BPC-157 research traces back to one group: Predrag Sikiric and colleagues at the University of Zagreb in Croatia. That matters, because a finding reproduced only by the lab that discovered it is weaker than one confirmed by independent teams.

1. 1Early 1990sThe Zagreb group begins publishing rat studies of the peptide on stomach ulcers and gut protection.
2. 21990s to 2000sThe Croatian drug company PLIVA takes BPC-157 into early testing for bowel inflammation; full results were never published in a peer-reviewed journal and it did not go on to approval.
3. 32003 onwardRat studies widen to tendons, muscle and ligaments, starting with a cut Achilles tendon study ².
4. 4Around 2010 onwardBPC-157 spreads online through bodybuilding and biohacking forums, sold as a 'research chemical' in vials labelled not for human use.
5. 52021 to 2026The first full human reports appear: small chart reviews and pilots from US private clinics ^{7 8 9}. FDA's stance on compounding shifts; see the legal section below.

How BPC-157 is thought to work

Every mechanism below was seen in rats, rat cells or dishes of cells. None has been confirmed in a living person.

What the research shows

The weight of BPC-157 evidence sits almost entirely at the bottom of the evidence ladder. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, and 35 of them were preclinical, meaning animal or cell work ¹.

The published human reports, by size

Added together, 33 people appear in published BPC-157 reports with usable data. None of the reports had a comparison group, and three of the four share a lead author and were run in private US clinics. Without a comparison group, a knee that feels better months later cannot be separated from natural recovery, other treatment or expectation.

Animal results versus human evidence by body area

If joint or tendon pain is what brought you here, the <a href="/symptoms/joint-pain">joint pain guide</a> covers the causes that do have tested treatments.

Is BPC-157 FDA-approved? Is it legal?

BPC-157 has never been approved by the FDA or any other national drug regulator. In 2023 FDA placed BPC-157 in Category 2 of its list of bulk ingredients for 503A pharmacies ¹². 503A pharmacies are state-licensed pharmacies that mix a medicine for one named patient on a prescription; Category 2 is FDA's list of ingredients it says may be unsafe for them to use. FDA's stated reasons were the risk of the immune system making antibodies against the injected peptide (immunogenicity), uncertainty about impurities and about exactly what the active ingredient is, and a lack of information on whether it harms people ¹².

1. 12023FDA lists BPC-157 in Category 2, ingredients that may present significant safety risks in compounding ¹².
2. 2April 2026FDA announces it will remove BPC-157 and 11 other peptides from Category 2 after their nominations were withdrawn. Removal alone does not make them legal to compound ¹³.
3. 3July 2026FDA's Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend BPC-157 for the 503A list, against the advice of FDA's own reviewers ¹⁴.
4. 4October 2026HHS (the US Department of Health and Human Services) issues an interim policy: it will not act against licensed pharmacies and physicians who compound BPC-157 and five other peptides on individual prescriptions, if they meet set conditions, until formal rules are finished ¹⁵.

As of November 2026, the conditions include buying the peptide from an FDA-registered facility, holding a certificate of analysis that shows it meets FDA testing criteria, and reporting serious side effects and quality problems to FDA ¹⁵. State pharmacy boards can still set their own limits.

BPC-157 side effects and risks

BPC-157 has no established human side-effect profile, because too few people have been studied. A preclinical safety programme in mice, rats, rabbits and dogs reported no serious toxicity ⁶, which does not establish safety in people. In its 2026 review, FDA flagged findings from repeated-dose animal studies as potentially relevant to people, including changes in clotting and in liver function, while noting that longer-term toxicity and cancer studies were not available ¹⁴.

• Cancer: in animal and cell studies BPC-157 switches on growth signals and grows new blood vessels, both of which tumours can use. FDA called the chance that it could help a tumour grow or spread a theoretical concern not established in humans, and noted that long-term cancer studies have not been done ¹⁴. No human study has tested it. If you have or have had cancer, raise BPC-157 with your oncologist before any use.
• Bleeding: because animal studies showed clotting changes, anyone on a blood thinner or antiplatelet drug or with a bleeding disorder should raise BPC-157 with their clinician before any use.
• Pregnancy and breastfeeding: there are no human data on BPC-157.
• Product quality: identity, dose, purity and sterility of online BPC-157 are unverified.
• Immune reactions: FDA flagged immunogenicity, the chance the body makes antibodies against an injected peptide ¹².

If you already take BPC-157: what to tell your doctor and which blood tests matter

Tell your doctor you use BPC-157, and tell any surgeon or dentist before a procedure, because the animal data flagged clotting changes. This matters most if you take a blood thinner or antiplatelet drug, such as warfarin, apixaban, rivaroxaban, clopidogrel or daily aspirin. Ask whether a baseline set of liver and clotting tests and a later repeat make sense for you, and get tested sooner if you notice bruising, bleeding or yellowing. You or your clinician can report a suspected reaction to FDA through MedWatch.

These tests can show a change worth discussing with your clinician; normal results do not show that BPC-157 is safe or that it is working. If ALT, AST, prothrombin time, INR or platelets come back outside the reference range, take them to your clinician rather than reading them alone. A high INR or low platelets together with bruising, nosebleeds, blood in urine or stool, or black stools needs care the same day.

For what each number means, see <a href="/learn/liver-enzymes-explained">liver enzymes explained</a> and <a href="/learn/clotting-tests-explained">clotting tests explained</a>. A hard workout can raise AST and ALT for a few days, so a result taken the morning after heavy lifting can read high for reasons unrelated to BPC-157.

Free, no accountRead your blood testHave a recent panel with liver enzymes or clotting results? Read every line of it, free.Read my results

Oral vs injectable BPC-157

No study has compared oral and injected BPC-157 in people, so nobody can say which works better. The two routes have been studied for different things.

BPC-157 and TB-500 (the 'Wolverine stack')

TB-500 is a synthetic peptide based on part of thymosin beta-4, a protein that binds actin, which cells use to move into wounds. The pairing of BPC-157 and TB-500 is nicknamed the Wolverine stack, after the comic-book character who heals from any wound. The only published human data on the pair are 4 knee patients in the 2021 chart review, 3 of whom said their pain improved ⁷.

Taking BPC-157 and TB-500 together adds a second untested peptide. Both promote blood-vessel growth in animals, neither has a human safety profile, and both are prohibited by WADA ¹⁶.

Is there a standard BPC-157 dose?

No human dose of BPC-157 has been established. No approved label exists, and the figures that circulate online are informal extrapolations from rodent studies. This page gives no dose numbers or mixing instructions.

Pentadeca arginate (PDA) and 'arginate salt' BPC-157

Pentadeca arginate, also called PDA or the PDA peptide, is marketed as an arginate salt form of BPC-157 or a close variant, with the claim that it is more stable. There is no published human evidence that PDA works differently from, better than or more safely than other forms of BPC-157. PDA carries the same gaps: no approval, no established dose, no controlled human trials, and the same purity questions when bought online.

If you train hard and want to track recovery with tested markers, <a href="/for/body-performance">body and performance</a> lists the ones worth watching.

Free, no accountDrop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.

Read my results Download the app